CELL INTELLIGENCE · 肿瘤细胞治疗研究

接受抗 CD38 与 BCMA 治疗的多发性骨髓瘤患者中巨细胞病毒再激活的前瞻性研究

Prospective Study of Cytomegalovirus Reactivation in Patients With Multiple Myeloma Receiving Anti-CD38 and BCMA Therapies.

在接受靶向 CD38 和 BCMA 药物的 MM 患者中，低水平 CMV 检出较为常见，但病毒血症通常具有自限性，在我们的研究队列中，尽管 CMV 检出率相对较高，却没有出现有症状的 CMV 感染。

四重暴露/难治性多发性骨髓瘤：既往接受过抗 CD38、IMiDs、蛋白酶体抑制剂与 BCMA 靶向治疗的患者

Quad-Exposed/Refractory Multiple Myeloma: Patients Previously Treated With Anti-CD38, IMiDs, Proteasome Inhibitors, and BCMA-Targeted Therapies.

SOHO 最新进展更新与后续问题：T-ALL 新型疗法：从 CAR-T 到新靶点

SOHO State of the Art Updates and Next Questions: Novel Therapies in T-ALL: From CAR-T to Novel Targets.

异基因造血细胞移植后高度难治性多发性骨髓瘤与治疗相关 MDS/AML 的持久缓解：CAR-T 时代其作用的再思考

Durable Remission of Highly Refractory Multiple Myeloma and Therapy-Related MDS/AML After Allogeneic Hematopoietic Cell Transplantation: Reconsidering

SOHO 最新进展与后续问题 | 骨髓瘤早期复发的治疗：非 CAR-T 细胞

SOHO State of the Art Updates and Next Questions | Treatment of Myeloma Early Relapse: Non-CAR T Cell.

Ciltacabtagene autoleucel 治疗复发/难治性多发性骨髓瘤的真实世界疗效结局：与 Cartitude-1 试验的比较研究

Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial.

我们的研究表明，cilta-cel 在真实世界（RW）环境下治疗的 RRMM 患者中疗效相当。

骨髓免疫生态系统塑造了浆细胞骨髓瘤中达雷妥尤单抗的获得性耐药

The bone marrow immune ecosystem shapes daratumumab acquired resistance in plasma cell myeloma.

多发性骨髓瘤的演变格局：从风险分层到 T 细胞导向的先进疗法

The Evolving Landscape in Multiple Myeloma: From Risk Stratification to T Cell-Directed Advanced Therapies.

CD38 作为肿瘤学中的诊疗靶点

CD38 as theranostic target in oncology.

CD38-CAR 人 NK 细胞联合 ATRA 增强对表达 CD38 的血液系统恶性肿瘤的细胞毒性

CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignancies.